Correspondence
Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations
Abstract
We thank Eckardt and Klein for their interest in our phase II trial delineating the treatment efficacy of regorafenib in patients with metastatic and/or an unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 (1). Several issues emerged (2).
